Three ain't a magic number!

A US district court ruling found that Elan breached its marketing and development agreement with Biogen Idec for Tysabri (natalizumab) due to a $1-billion deal the Irish drugmaker signed with Johnson & Johnson. The judge said that Biogen Idec, which asserted that the terms of the Tysabri collaboration had been violated by the deal, "is within its rights" to give Elan "the opportunity to cure that breach" by September 26. Full story